On August 24, Oklo Inc. declined 5.17% in regular trading, trading at $39.8 per share with turnover of approximately $59.57 million. The stock continued to face selling pressure from a combination of analyst forecast cuts and concentrated insider disposals.

On August 11, multiple analysts lowered their earnings projections following Q2 results, triggering a 7.7% drop at the time. The Q2 report, released August 7, showed EPS of -$0.28, missing the FactSet consensus estimate of -$0.16 by 75%, though revenue of $1.21 million significantly exceeded the $126,250 estimate and marked the company's first-ever quarterly revenue. Additionally, CEO Jacob DeWitte and COO Caroline Cochran each filed Form 144 plans to sell 400,000 shares of Class A common stock, totaling approximately $31.06 million in planned disposals. The concentrated insider selling further eroded market confidence.

Despite meaningful milestones in reactor commercialization — including DOE startup authorization for the Groves Isotope Test Reactor and achievement of criticality — widening near-term losses and high-profile executive share sales continue to pressure the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)